Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. - Wikidata - awgldk - TriplyDB

Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents.

Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents.

http://www.wikidata.org/entity/Q33391221

about

Advances in Diagnosis and Treatments for Immune Thrombocytopenia Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia Immune thrombocytopenia Piecing together the humoral and cellular mechanisms of immune thrombocytopenia The Centenary of Immune Thrombocytopenia - Part 1: Revising Nomenclature and Pathogenesis Eltrombopag for the treatment of aplastic anemia: current perspectives Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia.Interleukin-17F gene polymorphism in patients with chronic immune thrombocytopenia.Immunologic effects of rituximab on the human spleen in immune thrombocytopenia.Circulating plasmacytoid dendritic cells in patients with primary and Helicobacter pylori-associated immune thrombocytopenia.Pulsed high-dose dexamethasone improves interleukin 10 secretion by CD5+ B cells in patients with primary immune thrombocytopenia.Defective regulatory B-cell compartment in patients with immune thrombocytopenia CD4+ CD25+High Foxp3+ regulatory T cells, B lymphocytes, and T lymphocytes in patients with acute ITP in Assiut Children Hospital.Platelet Kinetics in Idiopathic Thrombocytopenic Purpura Patients Treated with Thrombopoietin Receptor Agonists.CD16+ monocytes control T-cell subset development in immune thrombocytopenia.The clinical significance of circulating B cells secreting anti-glycoprotein IIb/IIIa antibody and platelet glycoprotein IIb/IIIa in patients with primary immune thrombocytopenia.Positioning new treatments in the management of immune thrombocytopenia The beta 1 tubulin R307H single nucleotide polymorphism is associated with treatment failures in immune thrombocytopenia (ITP).Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists The efficacy and safety of romiplostim in adult patients with chronic immune thrombocytopenia.Immune dysregulation in immune thrombocytopenia.Immune thrombocytopenia -- what are the new treatment options?Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study.Cellular immune dysfunction in immune thrombocytopenia (ITP).Advances in immunopathogenesis of adult immune thrombocytopenia.Effects of rapamycin combined with low dose prednisone in patients with chronic immune thrombocytopenia.The role of T cell immunoglobulin and mucin domain-3 in immune thrombocytopenia.Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia.Novel treatments for immune thrombocytopenia.The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.Induction of immune tolerance to platelet antigen by short-term thrombopoietin treatment in a mouse model of immune thrombocytopenia.In vitro TNF blockade enhances ex vivo expansion of regulatory T cells in patients with immune thrombocytopenia Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.Insufficient secretion of IL-10 by Tregs compromised its control on over-activated CD4+ T effector cells in newly diagnosed adult immune thrombocytopenia patients.A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP.Altered cytokine levels in pediatric ITP.Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice.Neutralizations of IL-17A and IL-21 regulate regulatory T cell/T-helper 17 imbalance via T-helper 17-associated signaling pathway in immune thrombocytopenia.CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia.

P2860

Q26738630-04F7E3C9-B285-4C7E-8B05-A362A82210BF Q26741269-113CF797-C442-47ED-81B7-77A2998DE02A Q26830918-3B653F34-AD7F-4E55-A268-E601438AE048 Q27024841-54F3FD1D-2F4D-42FA-B2E3-585A9F30AEBC Q28068881-46423488-C8C0-44C2-AE23-ACC88D9B44A6 Q28071710-094F34E1-7D30-4793-8F70-3A1B02928AB2 Q33394438-5C4331F9-BFCA-4B14-9065-31DD48DB6191 Q33395519-F0BE2494-897D-4E94-A916-B1AB126785CC Q33396902-CAB1DD5B-61E6-4611-91AB-C3BD484806C8 Q33399044-2D1FEF6E-12A2-47B5-965A-FB86DC326685 Q33401624-51D653FB-F5AD-4F94-A433-6B2F13217BF1 Q33402659-CEB3E524-AF82-4CDE-85C7-6EFE9B2C2BAF Q33402738-2CFA496F-B5E8-42BE-BFBD-BC16930C057C Q33402843-DC25C55D-6DD7-4768-8223-0ABC15EE8E88 Q33402944-2115D436-8DEE-4920-B1BB-8A073C77D2C0 Q33403270-87F35333-99F3-4A7C-94A5-CB262BBBDA23 Q33404095-3E21F08D-BD2E-46C5-A8F5-B01DB5EF0176 Q33404408-3B279A31-DEEB-4B28-B06E-3599981CF186 Q33405820-58C4FCDD-852E-4347-B2FE-8CCE4DC5B559 Q33406176-DA0C1626-72C7-40CF-82ED-13C65A1A1001 Q33407279-D331A57E-8C4C-4AA4-82BE-C2FBD80C27DD Q33407649-84A76409-5962-417F-8F63-411729B03102 Q33407802-28CBB385-E25B-40BC-ABB7-78C675C36CDC Q33409401-5CCD058E-1262-47AE-8B1F-D1BCD978913B Q33409710-45A7D370-8BEA-4CBB-B511-65EE2357C957 Q33411672-5E148572-B8C1-4866-84EE-23920351BB9D Q33412264-C7179E8A-7CEC-4C27-9E5A-50BF8A168961 Q33412416-B6F21EDB-01CD-4AFD-9677-DB4F148CFD79 Q33413160-7CFB5D4E-EFDE-47F7-8757-2A9434422069 Q33414132-CA69BA5D-2AA7-4B4D-954B-E8368C4D5D6B Q33414573-F7BE20DB-036C-4EF6-8CF4-96446285E9B1 Q33417625-E5B78655-5712-4E5F-974D-4CFFDBEFCF1F Q33417826-98A3067B-E489-42F7-AD7D-B28AF31785B1 Q33418722-F66DCD4F-A741-4A4E-8A99-72FCD75C2AB5 Q33419551-571C8DCD-68C9-4BAD-86CB-B77A4E97A8E2 Q33419712-017EB4F2-5C8F-4C45-81B2-F6682925C067 Q33421423-ED8004BE-5D1E-44D0-96AF-0D4C4F674475 Q33421783-2560EFBC-D3A8-418B-BE49-8A3E4426CA85 Q33422836-C67C609A-AB84-4B5A-86EF-2D099531D756 Q33423336-55A3DE55-4FB0-4084-8654-580A38ED6380

P2860

Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents.

http://www.wikidata.org/entity/Q33391221

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Improved regulatory T-cell act ...... ed with thrombopoietic agents.

@ast

Improved regulatory T-cell act ...... ed with thrombopoietic agents.

@en

type

label

Improved regulatory T-cell act ...... ed with thrombopoietic agents.

@ast

Improved regulatory T-cell act ...... ed with thrombopoietic agents.

@en

prefLabel

Improved regulatory T-cell act ...... ed with thrombopoietic agents.

@ast

Improved regulatory T-cell act ...... ed with thrombopoietic agents.

@en

P1433

Q33391221-E43188EF-F224-4479-A4B8-8828E738C0EC

P1476

Q33391221-BBE21BD7-81E5-42AD-AB33-A51F4309EBFC

P2093

Q33391221-43AE9836-B199-4750-8788-B2F190D20F9C

Q33391221-CB8C6DE5-184A-47F9-8A93-C9F095A2598D

Q33391221-CFD3B1CE-DCE2-49EB-A37B-99338AA232D3

Q33391221-D6ACA9A1-9A41-4039-B65A-144470E44CA3

Q33391221-E5682E71-9313-43D7-9AD9-BEAAF19A4844

Q33391221-F054F4FC-390F-4952-9BCC-52FFBE96FD98

P2860

Q33391221-09DEE1EC-A2E5-4F2B-946C-A0758B7FE5BA

Q33391221-198477F5-F6F9-46C1-9DC6-0E6490778E2E

Q33391221-1EF0F053-DBD8-43CD-810C-E1A1217D04AF

Q33391221-257E9E86-6B2C-425A-B65E-D8131442ECAD

Q33391221-28EF4302-FB94-4C8F-A88D-A4A44214AE31

Q33391221-387DCA57-729F-40DE-B82B-77F559D86090

Q33391221-3BA02200-B424-40AF-93F9-26160F60B8C8

Q33391221-3EDE1A43-BDF3-409C-807F-C1629B2ACDC9

Q33391221-5415FD7D-DD57-4AFC-BDDC-68D5AB477716

Q33391221-57A6223C-1A7B-4B1C-ADF5-098A28B77F62

P304

Q33391221-7445F052-2573-4649-B0A5-CF5BFC4C8CEF

P31

Q33391221-AC4C8423-06FB-4C39-9A52-D92C10567599

P356

Q33391221-2CF5E5DC-3607-41EE-B8C6-DA227064A9E0

P407

Q33391221-8302FD94-EA43-4866-86C6-109AFCDBCA61

P433

Q33391221-E653DD6B-077C-43C4-AD72-382F515F8690

P478

Q33391221-A038E732-A9A7-4DF5-92DF-4F54AFF4F7E1

P50

Q33391221-496E052B-7522-48FB-8806-A0C280D3AF60

P577

Q33391221-515539D0-C0F4-4DCE-955B-21B387BF77D0

P5875

Q33391221-5F850E9B-C7B2-485C-81FC-4351298DAEF7

P698

Q33391221-8E592B8D-A918-4B05-8892-A8DB358B11FC

P921

Q33391221-A687E382-4B77-44AB-92D1-980F00888876

P932

Q33391221-A2C9D8B4-5622-49CB-B000-14F0BBBF4FE6

P356

BLOOD-2010-04-281717

P1433

P1476

Improved regulatory T-cell act ...... ed with thrombopoietic agents.

@en

P2093

Karina Yazdanbakhsh

http://www.w3.org/2001/XMLSchema#string

Marissa Karpoff

http://www.w3.org/2001/XMLSchema#string

Nayla Boulad

http://www.w3.org/2001/XMLSchema#string

Susanne Heck

http://www.w3.org/2001/XMLSchema#string

Weili Bao

http://www.w3.org/2001/XMLSchema#string

Wu He

http://www.w3.org/2001/XMLSchema#string

P2860

Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody

Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura

Making sense of latent TGFbeta activation

Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab

Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia

Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity

Mechanisms of foxp3+ T regulatory cell-mediated suppression

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts.

P304

4639-4645

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-04-281717

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45508356

http://www.w3.org/2001/XMLSchema#string

P698

20688957

http://www.w3.org/2001/XMLSchema#string

P921

thrombocytopenia

P932

2996119

http://www.w3.org/2001/XMLSchema#string